Shimai Pharmaceutical

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Zhejiang Shimai Pharmaceutical Co., Ltd., a T-cell engager (TCE) specialist founded in 2017, has filed...

CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors

Fineline Cube Apr 28, 2025

Zhejiang-based Zhejiang Shimai Pharmaceutical Co.，Ltd (CentryMed)’s CMDE005, an anti-EGFR×CD3 enzyme-controlled bispecific antibody (BsAb) developed using...

Shimai Pharmaceutical

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors

You Missed

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis